Previous 10 | Next 10 |
2023-04-04 14:00:00 ET Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating billion-dollar revenue for years, thanks to its portfolio of cystic fibrosis (CF) drugs. In fact, Vertex is the global leader in CF treatment and likely to hang onto that position for quite some time. B...
2023-04-03 08:39:07 ET Vertex Pharmaceuticals ( NASDAQ: VRTX ) and CRISPR Therapeutics ( CRSP ) have completed a rolling submission of a Biologics License Application to the US FDA for exagamglogene autotemcel (exa-cel) for sickle cell disease and transfusion-dependent bet...
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics Licens...
2023-04-01 05:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) is heading for an important moment: the potential approval of its first product, exa-cel to treat blood disorders. That's a good reason to buy the stock now and benefit down the road. And this week, the company announced ...
2023-03-31 04:07:54 ET Summary CTX001 has progressed enough to start discussing details regarding the launch of the program. Regulatory decisions, likely carrying an approval, will likely come in the coming quarters. Potential CTX001 is massive with attractive potential pricin...
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures...
2023-03-27 08:24:11 ET Vertex Pharmaceuticals ( NASDAQ: VRTX ) has signed a licensing deal with CRISPR Therapeutics ( NASDAQ: CRSP ) to accelerate development of its hypoimmune cell therapies for the treatment of type 1 diabetes (T1D). As part of the deal, Vertex (...
-Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront payment plus milestone and royalty payments on potential future gene-edited hypoim...
2023-03-27 06:00:00 ET CRISPR Therapeutics (NASDAQ: CRSP) has a couple of things in common with a company that's made the headlines over the past few years: coronavirus vaccine maker Moderna (NASDAQ: MRNA) . No, CRISPR, isn't working on a coronavirus vaccine. But the company...
2023-03-25 09:30:00 ET Sometimes a company pioneers a brand-new technology, turning an industry on its head. Tesla did that to the automotive industry. After gas engines had been the standard for over a century, this newcomer showed that the future could be electric. The biotech ind...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website: